673 Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, open-label, single-arm, phase II study | Zendy

AI Assistant Blog Pricing

673 Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, open-label, single-arm, phase II study

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.